The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes coronavirus disease 2019 (COVID-19) and was declared a pandemic by the World Health Organization (WHO) on 11 March 2020. Herd or community immunity has been proposed as a strategy to protect the vulnerable, and can be established through immunity from past infection or vaccination. Whether SARS-CoV-2 infection results in the development of a reservoir of resilient memory cells is under investigation. Vaccines have been developed at an unprecedented rate and 7 408 870 760 vaccine doses have been administered worldwide. Recently emerged SARS-CoV-2 variants are more transmissible with a reduced sensitivity to immune mechanisms. This is due to the presence of amino acid substitutions in the spike protein, which confer a selective advantage. The emergence of variants therefore poses a risk for vaccine effectiveness and long-term immunity, and it is crucial therefore to determine the effectiveness of vaccines against currently circulating variants. Here we review both SARS-CoV-2-induced host immune activation and vaccine-induced immune responses, highlighting the responses of immune memory cells that are key indicators of host immunity. We further discuss how variants emerge and the currently circulating variants of concern (VOC), with particular focus on implications for vaccine effectiveness. Finally, we describe new antibody treatments and future vaccine approaches that will be important as we navigate through the COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 1×
“Despite the low frequency of RBD in the open position, RBM ACE2 receptor affinity is high (98).”
BackgroundDysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775 · cited 1×
“T-cell lymphopenia, particularly the CD4 T-lymphocyte subset, and an increased neutrophil to lymphocyte ratio (NLR) (indicator of inflammation) has also been observed in COVID-19 patients and correlates with disease severity (34).”
BackgroundVoysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,948
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · cited 1×
“Antibodies directed against the RBD of the S protein demonstrate neutralizing ability and SARS-CoV-2 neutralizing immunoglobulins (Ig)A, IgM and IgG have been identified in COVID-19 patients (39) with IgM being produced first (38, 40).”
BackgroundImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 3×
“Similarly, it was found that B-lymphocyte memory cells were stable for six months after infection and accumulated more in patients with severe disease with IgG being the most dominant isotype (52, 57, 58).”
BackgroundEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science · doi:10.1126/science.abd2985 · Cited by 1,925
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
T follicular helper cell differentiation, function, and roles in disease
Crotty, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.004 · Cited by 1,847
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · cited 2×
“(59) found that B-lymphocyte memory cells do not decay after six months but rather evolves and can mount an effective response against the virus upon re-exposure (59).”
BackgroundSix Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J.-Q., Du, P., Wei, D., Zhang, Y., Sun, X.-X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,593
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Neuropilin-1 is a host factor for SARS-CoV-2 infection
Daly, J. L., Simonetti, B., Klein, K., Chen, K.-E., Williamson, M. K., Antón-Plágaro, C., Shoemark, D. K., Simón-Gracia, L., Bauer, M., Hollandi, R., et al. (2020) · Science · doi:10.1126/science.abd3072 · Cited by 1,251
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
Mucins in the mucosal barrier to infection
Linden, S. K., Sutton, P., Karlsson, N. G., Korolik, V, & McGuckin, M. A. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.5 · Cited by 1,234
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221 · cited 1×
“proposes that furin cleavage during virus packing may preactivate the protein for membrane fusion independent of target cell receptor ACE2 binding or proteases and could lead to spontaneous S1 dissociation in mature virions (101).”
BackgroundGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02183-8 · Cited by 1,167
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · doi:10.1101/2021.06.21.21258528 · Cited by 1,163
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
Herd Immunity: Understanding COVID-19
Randolph, H. E., & Barreiro, L. B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.012 · Cited by 1,138
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120 · cited 1×
“Interestingly, pre-existing memory CD4 and CD8 Tlymphocytes potentially effective against SARS-CoV-2 were found in people with no history of COVID-19 infection or vaccination (53).”
BackgroundImmune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,119
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool
O’Toole, Á., Scher, E., Underwood, A., Jackson, B., Hill, V., McCrone, J. T., Colquhoun, R., Ruis, C., Abu-Dahab, K., Taylor, B., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab064 · Cited by 1,077
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.037 · Cited by 992
Self-citationActivation and evasion of type I interferon responses by SARS-CoV-2
Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L., Ren, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17665-9 · Cited by 980
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873
Evidence for antibody as a protective correlate for COVID-19 vaccines
Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.063 · Cited by 870
Bonilla, F. A., & Oettgen, H. C. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.017 · Cited by 839
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021
Campbell, F., Archer, B., Laurenson-Schafer, H., Jinnai, Y., Konings, F., Batra, N., Pavlin, B., Vandemaele, K., Van Kerkhove, M. D., Jombart, T., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.24.2100509 · Cited by 819
T cell responses in patients with COVID-19
Chen, Z., & John Wherry, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0402-6 · Cited by 797
COVID-19: a new virus, but a familiar receptor and cytokine release syndrome
Hirano, T., & Murakami, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.003 · Cited by 772
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
Kaneko, N., Kuo, H.-H., Boucau, J., Farmer, J. R., Allard-Chamard, H., Mahajan, V. S., Piechocka-Trocha, A., Lefteri, K., Osborn, M., Bals, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.025 · Cited by 734
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00908-w · Cited by 731
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · doi:10.1101/2021.04.22.440932 · Cited by 730
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071542 · Cited by 730
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
COVID-19 vaccines: modes of immune activation and future challenges
Teijaro, J. R., & Farber, D. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00526-x · Cited by 701
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
Abdool Karim, S. S., & de Oliveira, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2100362 · Cited by 699
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Goel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647
Self-citationDynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A. P., Maruste, R., Kärner, J., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100208 · Cited by 645
Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
Zhu, Z., Lian, X., Su, X., Wu, W., Marraro, G. A., & Zeng, Y. (2020) · Respiratory Research · doi:10.1186/s12931-020-01479-w · Cited by 614
Genetic Variants of SARS-CoV-2—What Do They Mean?
Lauring, A. S., & Hodcroft, E. B. (2021) · JAMA · doi:10.1001/jama.2020.27124 · Cited by 604
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583
Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
Tarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540
SARS-CoV-2 spike D614G change enhances replication and transmission
Zhou, B., Thao, T. T. N., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A., King, J., Steiner, S., Kelly, J. N., et al. (2021) · Nature · doi:10.1038/s41586-021-03361-1 · Cited by 538
Natural selection and infectious disease in human populations
Karlsson, E. K., Kwiatkowski, D. P., & Sabeti, P. C. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3734 · Cited by 534
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
Zhou, R., To, K. K.-W., Wong, Y.-C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.-Y., Lau, T. T.-K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.026 · Cited by 531
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 529
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. (2021) · Science · doi:10.1126/science.abg6105 · Cited by 515
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Sarkar, R., Türeci, Ö., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.18.426984 · Cited by 515
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508 · cited 1×
“Antibodies directed against the RBD of the S protein demonstrate neutralizing ability and SARS-CoV-2 neutralizing immunoglobulins (Ig)A, IgM and IgG have been identified in COVID-19 patients (39) with IgM being produced first (38, 40).”
BackgroundMackenzie, J. S., & Smith, D. W. (2020) · Microbiology Australia · doi:10.1071/ma20013 · Cited by 507
Brown, C. M., Vostok, J., Johnson, H., Burns, M., Gharpure, R., Sami, S., Sabo, R. T., Hall, N., Foreman, A., Schubert, P. L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7031e2 · Cited by 504
Coronaviruses: An RNA proofreading machine regulates replication fidelity and diversity
Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D., & Baric, R. S. (2011) · RNA Biology · doi:10.4161/rna.8.2.15013 · Cited by 476
Burbelo, P. D., Riedo, F. X., Morishima, C., Rawlings, S., Smith, D., Das, S., Strich, J. R., Chertow, D. S., Davey, R. T., & Cohen, J. I. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa273 · Cited by 471
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
Eyre, D. W., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. E. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116597 · Cited by 464
Innate immune response to viral infection
Koyama, S., Ishii, K. J., Coban, C., & Akira, S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.009 · Cited by 463
Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, C., Nyhoff, L. E., Edara, V. V., Floyd, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100354 · Cited by 441
Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419
Simmons, G., Zmora, P., Gierer, S., Heurich, A., & Pöhlmann, S. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.028 · Cited by 413
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Meng, B., Kemp, S. A., Papa, G., Datir, R., Ferreira, I. A. T. M., Marelli, S., Harvey, W. T., Lytras, S., Mohamed, A., Gallo, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109292 · Cited by 405
Emergence of SARS-CoV-2 through recombination and strong purifying selection
Li, X., Giorgi, E. E., Marichannegowda, M. H., Foley, B., Xiao, C., Kong, X.-P., Chen, Y., Gnanakaran, S., Korber, B., & Gao, F. (2020) · Science Advances · doi:10.1126/sciadv.abb9153 · Cited by 400
Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
Russell, M. W., Moldoveanu, Z., Ogra, P. L., & Mestecky, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611337 · Cited by 389
Normal Structure, Function, and Histology of Mucosa-Associated Lymphoid Tissue
Cesta, M. F. (2006) · Toxicologic Pathology · doi:10.1080/01926230600865531 · Cited by 384
Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383
Fung, S.-Y., Yuen, K.-S., Ye, Z.-W., Chan, C.-P., & Jin, D.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1736644 · Cited by 381
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378
SARS-CoV-2 Variants and Vaccines
Krause, P. R., Fleming, T. R., Longini, I. M., Peto, R., Briand, S., Heymann, D. L., Beral, V., Snape, M. D., Rees, H., Ropero, A.-M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmsr2105280 · Cited by 366
Saadat, S., Rikhtegaran Tehrani, Z., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M. M. (2021) · JAMA · doi:10.1001/jama.2021.3341 · Cited by 364
Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2
Di Giorgio, S., Martignano, F., Torcia, M. G., Mattiuz, G., & Conticello, S. G. (2020) · Science Advances · doi:10.1126/sciadv.abb5813 · Cited by 355
Nomenclature for Immune Correlates of Protection After Vaccination
Plotkin, S. A., & Gilbert, P. B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis238 · Cited by 347
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
Sette, A., & Crotty, S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0389-z · Cited by 347
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
Sokal, A., Chappert, P., Barba-Spaeth, G., Roeser, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Fernandez, I., Meola, A., Bouvier-Alias, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.050 · Cited by 340 · cited 1×
“Similarly, it was found that B-lymphocyte memory cells were stable for six months after infection and accumulated more in patients with severe disease with IgG being the most dominant isotype (52, 57, 58).”
BackgroundChia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J.-M., Mak, T.-M., Cui, L., Kalimuddin, S., Chia, W. N., Tan, C. W., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.010 · Cited by 331
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
Le Bert, N., Clapham, H. E., Tan, A. T., Chia, W. N., Tham, C. Y. L., Lim, J. M., Kunasegaran, K., Tan, L. W. L., Dutertre, C.-A., Shankar, N., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202617 · Cited by 330
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01410-w · Cited by 326
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.10.011 · Cited by 322
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
A potential role for integrins in host cell entry by SARS-CoV-2
Sigrist, C. J., Bridge, A., & Le Mercier, P. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104759 · Cited by 314
Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaill, J., Pillet, S., Grattard, F., Gonzalo, S., Verhoeven, P., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00588-2 · Cited by 305
Hartley, G. E., Edwards, E. S. J., Aui, P. M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A. Y., Boo, I., Drummer, H. E., Hogarth, P. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf8891 · Cited by 296
Alanagreh, L., Alzoughool, F., & Atoum, M. (2020) · Pathogens · doi:10.3390/pathogens9050331 · Cited by 291
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283
Ogando, N. S., Zevenhoven-Dobbe, J. C., van der Meer, Y., Bredenbeek, P. J., Posthuma, C. C., & Snijder, E. J. (2020) · Journal of Virology · doi:10.1128/jvi.01246-20 · Cited by 282
How bad is Omicron? What scientists know so far
Callaway, E., & Ledford, H. (2021) · Nature · doi:10.1038/d41586-021-03614-z · Cited by 277
Broad sarbecovirus neutralization by a human monoclonal antibody
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., Di Iulio, J., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03817-4 · Cited by 266
Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021
Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7032e1 · Cited by 240
Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic
Jackson, B., Boni, M. F., Bull, M. J., Colleran, A., Colquhoun, R. M., Darby, A. C., Haldenby, S., Hill, V., Lucaci, A., McCrone, J. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.014 · Cited by 238
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n296 · Cited by 235
The effect of spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108890 · Cited by 215
The Immune Response and Immunopathology of COVID-19
Mortaz, E., Tabarsi, P., Varahram, M., Folkerts, G., & Adcock, I. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02037 · Cited by 209
Adjuvants for Coronavirus Vaccines
Liang, Z., Zhu, H., Wang, X., Jing, B., Li, Z., Xia, X., Sun, H., Yang, Y., Zhang, W., Shi, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589833 · Cited by 197
Elliott, P., Haw, D., Wang, H., Eales, O., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., et al. (2021) · Science · doi:10.1126/science.abl9551 · Cited by 193
Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J., Walker, A. J., Hickman, G., Nightingale, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.11.2100256 · Cited by 189
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 188
Understanding variants of SARS-CoV-2
Burki, T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00298-1 · Cited by 186
Human IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski, A. V., Campillo Luna, J., & Redlich, C. A. (2021) · PLOS ONE · doi:10.1371/journal.pone.0249499 · Cited by 179
A correlate of protection for SARS-CoV-2 vaccines is urgently needed
Krammer, F. (2021) · Nature Medicine · doi:10.1038/s41591-021-01432-4 · Cited by 179
Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan
Fujino, T., Nomoto, H., Kutsuna, S., Ujiie, M., Suzuki, T., Sato, R., Fujimoto, T., Kuroda, M., Wakita, T., & Ohmagari, N. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2704.210138 · Cited by 177
Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN
Moeller, N. H., Shi, K., Demir, Ö., Belica, C., Banerjee, S., Yin, L., Durfee, C., Amaro, R. E., & Aihara, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106379119 · Cited by 177
Monocytes and macrophages in COVID-19: Friends and foes
Meidaninikjeh, S., Sabouni, N., Marzouni, H. Z., Bengar, S., Khalili, A., & Jafari, R. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.119010 · Cited by 172
Neutrophils and COVID-19: The road so far
Cavalcante-Silva, L. H. A., Carvalho, D. C. M., Lima, É. D. A., Galvão, J. G. F. M., da Silva, J. S. D. F., Sales-Neto, J. M. D., & Rodrigues-Mascarenhas, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107233 · Cited by 166
SARS-CoV-2 Viral Variants—Tackling a Moving Target
Mascola, J. R., Graham, B. S., & Fauci, A. S. (2021) · JAMA · doi:10.1001/jama.2021.2088 · Cited by 163
The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant
Ali, F., Kasry, A., & Amin, M. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100086 · Cited by 163
Innate and adaptive immune responses against coronavirus
Hosseini, A., Hashemi, V., Shomali, N., Asghari, F., Gharibi, T., Akbari, M., Gholizadeh, S., & Jafari, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110859 · Cited by 162
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection
Smith, N., Goncalves, P., Charbit, B., Grzelak, L., Beretta, M., Planchais, C., Bruel, T., Rouilly, V., Bondet, V., Hadjadj, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01028-7 · Cited by 162
Covid-19: Perspectives on Innate Immune Evasion
Taefehshokr, N., Taefehshokr, S., Hemmat, N., & Heit, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580641 · Cited by 160
Stabilizing the closed SARS-CoV-2 spike trimer
Juraszek, J., Rutten, L., Blokland, S., Bouchier, P., Voorzaat, R., Ritschel, T., Bakkers, M. J. G., Renault, L. L. R., & Langedijk, J. P. M. (2021) · Nature Communications · doi:10.1038/s41467-020-20321-x · Cited by 158
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell
Puray‐Chavez, M., LaPak, K. M., Schrank, T. P., Elliott, J. L., Bhatt, D. P., Agajanian, M. J., Jasuja, R., Lawson, D. Q., Davis, K., Rothlauf, P. W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109364 · Cited by 150
Severe COVID-19 and aging: are monocytes the key?
Pence, B. D. (2020) · GeroScience · doi:10.1007/s11357-020-00213-0 · Cited by 146
Tarhini, H., Recoing, A., Bridier‐Nahmias, A., Rahi, M., Lambert, C., Martres, P., Lucet, J., Rioux, C., Bouzid, D., Lebourgeois, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab075 · Cited by 146
CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
Landras, A., de Moura, C. R., Jouenne, F., Lebbé, C., Ménashi, S., & Mourah, S. (2019) · Cancers · doi:10.3390/cancers11111803 · Cited by 145
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 144
Freitas, A. R. R., Beckedorff, O. A., Cavalcanti, L. P. D. G., Siqueira, A. M., de Castro, D. B., da Costa, C. F., Lemos, D. R. Q., & de Barros, E. N. C. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100021 · Cited by 139
Murine Coronavirus with an Extended Host Range Uses Heparan Sulfate as an Entry Receptor
de Haan, C. A. M., Li, Z., Lintelo, E. G. T., Bosch, B., Haijema, B. J., & Rottier, P. J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14451-14456.2005 · Cited by 137
Regulation of IFN-γ Signaling Is Essential for the Cytotoxic Activity of CD8+ T Cells
Tau, G. Z., Cowan, S., Weisburg, J. H., Braunstein, N. S., & Rothman, P. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5574 · Cited by 133
Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection
Zhou, Z. L., Zhang, X., Lei, X., Xiao, X., Jiao, T., Ma, R., Dong, X., Jiang, Q., Wang, W., Shi, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00800-3 · Cited by 124
Ko, J., Joo, E., Park, S., Baek, J. Y., Kim, W. D., Jee, J., Kim, C., Jeong, C., Kim, Y.-J., Shon, H. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072268 · Cited by 121
Francisco, R. D. S., Benites, L. F., Lamarca, A. P., de Almeida, L. G. P., Hansen, A. W., Gularte, J. S., Demoliner, M., Gerber, A. L., Guimarães, A. P. D. C., Eisen, A. K. A., et al. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198345 · Cited by 119
Antibody Response After SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review
Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. G., Anderson, J., Paynter, R. A., & Mackey, K. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7547 · Cited by 118
Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infectionPreprint
Karim, F., Moosa, M.-Y. S., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, J., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21258228 · Cited by 115
A COVID-19 Vaccine: Big Strides Come with Big Challenges
Mellet, J., & Pepper, M. S. (2021) · Vaccines · doi:10.3390/vaccines9010039 · Cited by 113
Self-citationDual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation
King, C., & Sprent, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.003 · Cited by 111
Yadav, P. D., Sapkal, G. N., Ella, R., Sahay, R. R., Nyayanit, D. A., Patil, D. Y., Deshpande, G. R., Shete, A. M., Gupta, N., Mohan, V., et al. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab104 · Cited by 108
Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection
Kumar, S., Nyodu, R., Maurya, V. K., & Saxena, S. K. (2020) · Medical virology · doi:10.1007/978-981-15-4814-7_5 · Cited by 107
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmissionPreprint
Eyre, D., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K., Walker, A., & Peto, T. (2021) · medRxiv · doi:10.1101/2021.09.28.21264260 · Cited by 105
Virus vaccines: proteins prefer prolines
Sanders, R. W., & Moore, J. P. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.002 · Cited by 104
Chan, C.-M., Chu, H., Wang, Y., Wong, B. H., Zhao, X., Zhou, J., Yang, D., Leung, S. P., Chan, J. F., Yeung, M. L., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01133-16 · Cited by 100
Plasma Cells, the Next Generation: Beyond Antibody Secretion
Pioli, P. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02768 · Cited by 99
Long‐term coexistence of SARS‐CoV‐2 with antibody response in COVID‐19 patients
Wang, B., Wang, L., Kong, X., Geng, J., Xiao, D., Ma, C., Jiang, X., & Wang, P. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25946 · Cited by 97
Host-directed editing of the SARS-CoV-2 genome
Mourier, T., Sadykov, M., Carr, M. J., González, G., Hall, W. W., & Pain, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.092 · Cited by 96
Villoutreix, B. O., Cálvez, V., Marcelin, A., & Khatib, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041695 · Cited by 96
Hematological findings in SARS patients and possible mechanisms (Review)
Yang, M., Li, C. K., Li, K., Hon, K. E., Ng, M. Y., Chan, P. K. S., & Fok, T. F. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.14.2.311 · Cited by 94
Mlcochova, P., Kemp, S., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T., Ferreira, I., Datir, R., et al. (2021) · doi:10.1101/2021.05.08.443253 · Cited by 90
Gupta, T., & Gupta, S. K. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106717 · Cited by 90
Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3Preprint
Naveca, F. G., da Costa, C. F., do Nascimento, V. A., de Souza, V. C., Corado, A. D. L. G., Nascimento, F., Costa, Á., Duarte, D., Silva, G., Mejía, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-318392/v1 · Cited by 90
IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
Quinti, I., Mortari, E. P., Salinas, A. F., Milito, C., & Carsetti, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.655896 · Cited by 89
COVID-19 makes B cells forget, but T cells remember
Cañete, P. F., & Vinuesa, C. G. (2020) · Cell · doi:10.1016/j.cell.2020.09.013 · Cited by 83
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
How to redesign COVID vaccines so they protect against variants
Callaway, E., & Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-00241-6 · Cited by 78
SARS-CoV-2: Possible recombination and emergence of potentially more virulent strains
Haddad, D., John, S. E., Mohammad, A., Hammad, M. M., Hebbar, P., Channanath, A. M., Nizam, R., Al-Qabandi, S., Madhoun, A. S. A., Alshukry, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251368 · Cited by 76
A ‘mix and match’ approach to SARS-CoV-2 vaccination
Deming, M. E., & Lyke, K. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01463-x · Cited by 76
T-cell dysregulation in COVID-19
Kalfaoglu, B., Almeida‐Santos, J., Tye, C. A., Satou, Y., & Lab), M. O. (. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.079 · Cited by 73
Dynamic changes in monocytes subsets in COVID-19 patients
Qin, S., Jiang, Y., Wei, X., Liu, X., Guan, J., Chen, Y., Lu, H., Qian, J., Wang, Z., & Lin, X. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.12.010 · Cited by 71
Naturally activated adaptive immunity in COVID‐19 patients
Yang, X., Dai, T., Zhou, X., Qian, H., Guo, R., Lei, L., Zhang, X., Zhang, D., Shi, L., Cheng, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15771 · Cited by 67
Rapid replacement of the Beta variant by the Delta variant in South AfricaPreprint
Tegally, H., Wilkinson, E., Althaus, C. L., Giovanetti, M., San, J. E., Giandhari, J., Pillay, S., Naidoo, Y., Ramphal, U., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.09.23.21264018 · Cited by 63
Self-citationOngoing Recombination in SARS-CoV-2 Revealed through Genealogical Reconstruction
Ignatieva, A., Hein, J., & Jenkins, P. A. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac028 · Cited by 59
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
Karim, S. S. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00468-2 · Cited by 52
Extended interval BNT162b2 vaccination enhances peak antibody generation
Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B., Otter, A., Zuo, J., & Moss, P. (2022) · npj Vaccines · doi:10.1038/s41541-022-00432-w · Cited by 52
Metadata
- Authors
- Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-03
- Volume
- 12
- Pages
- 809244-809244
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4206545113
- Cited by
- 299
- References
- 221
- FWCI
- 33.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.